SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales figure stood at Rs. 3624.27 millions for the December 2023 quarter. The mentioned figure indicates a growth of about 43.85% as compared to Rs. 2519.48 millions during the year-ago period.The Total Profit for the quarter ended December 2023 of Rs. 693.01 millions grew from Rs.-571.24 millions Operating profit Margin for the quarter ended December 2023 improved to 292.65% as compared to -267.29% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 3624.27 2519.48 43.85 10429.24 7623.67 36.80 10724.32 9429.27 13.73
Other Income 99.42 154.33 -35.58 233.49 380.58 -38.65 418.48 420.68 -0.52
PBIDT 292.65 -267.29 -209.49 436.74 -461.22 -194.69 -510.65 -14.86 3336.41
Interest 23.62 17.60 34.20 86.62 64.48 34.34 93.80 20.74 352.27
PBDT 949.18 -284.89 -433.17 1030.27 -575.92 -278.89 -1731.09 -35.60 4762.61
Depreciation 256.17 286.35 -10.54 802.39 776.62 3.32 1059.79 831.88 27.40
PBT 693.01 -571.24 -221.32 227.88 -1352.54 -116.85 -2790.88 -867.48 221.72
TAX 0.00 0.00 0.00 0.00 206.12 0.00 206.12 -313.18 -165.82
Deferred Tax 0.00 0.00 0.00 0.00 206.12 0.00 206.12 -315.55 -165.32
PAT 693.01 -571.24 -221.32 227.88 -1558.66 -114.62 -2997.00 -554.30 440.68
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) 8.07 -10.61 -176.11 4.19 -6.05 -169.22 -4.76 -0.16 2921.32

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×